2. Academic Validation
  3. Elafin is a biomarker of graft-versus-host disease of the skin

Elafin is a biomarker of graft-versus-host disease of the skin

  • Sci Transl Med. 2010 Jan 6;2(13):13ra2. doi: 10.1126/scitranslmed.3000406.
Sophie Paczesny 1,  Thomas M Braun,  John E Levine,  Jason Hogan,  Jeffrey Crawford,  Bryan Coffing,  Stephen Olsen,  Sung W Choi,  Hong Wang,  Vitor Faca,  Sharon Pitteri,  Qing Zhang,  Alice Chin,  Carrie Kitko,  Shin Mineishi,  Gregory Yanik,  Edward Peres,  David Hanauer,  Ying Wang,  Pavan Reddy,  Samir Hanash,  James L M Ferrara
Affiliations

Affiliation

  • 1 Department of Pediatrics, University of Michigan, Ann Arbor, MI 48109, USA.
PMID: 20371463 DOI: 10.1126/scitranslmed.3000406
Abstract

Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.

Figures
Products